treat Archives - PPM Healthcare

April 20, 2023

Doctor says women with endometriosis being told outdated myths to treat disease

Awareness close to endometriosis and that it is not usual to have intense ache with your periods is growing.

However, gynaecologist and endometriosis specialist Dr Michael Wynn-Williams explained some medical myths like prescribing being pregnant as a therapy or treatment are challenging to shake.

“We know from investigate that is been done in Australia that numerous women of all ages get advised ‘you’ve received endometriosis you need to have to get expecting, and you require to get expecting straight absent.’

“That is usually by family members members who have professional endometriosis and have been advised the exact point, but also by overall health specialists and which is genuinely challenging,” he said.

One particular person who been given such assistance was Caitlin.

When she reported to the professional she did not want kids, she was informed to hold out a year on the delivery handle, Mirena, before they would even think about medical procedures to address her endometriosis.

The professional educated Caitlin her selection not to have young children designed them hesitant to operate.

“It variety of felt like a little bit like I was being dealt with like a uterus, like the relaxation of me didn’t make a difference,” she said.

Disappointed with that answer, Caitlin went to a private surgeon in Christchurch who confirmed she experienced significant endometriosis.

Caitlin had to consider a 7 days annual go away to acquire her surgery, mainly because many thanks to her endo she experienced by now fatigued her ill leave.

Chief Executive of Endometriosis New Zealand Tanya Cooke mentioned there is even now a good deal of stigma all around the issue in the office.

“We know that from exploration carried out very last yr in New Zealand that 75 p.c of the members have been terrified to notify their employer or their bus that they have endo.

“We also know from analysis in Australia that just one in 6 people today with endo have truly lost their position,” she explained.

On the other hand, function is below way to enhance the life of all those with endometriosis in this region.

“We’ve been operating on the Women’s Wellbeing Technique submission, and we have carried out a great deal of work around finishing that submission.

“And as an organisation we would like to see the New Zealand govt develop an endometriosis motion plan.

This is some thing Dr Wynn-Williams has professional first-hand while operating in Australia when they launched their national action strategy.

“I saw the change that that made to education and learning to clients, to wellbeing practitioners, to enhancement in scientific exercise and pointers, but also funding to research,” he mentioned.

That submission is now in front of the Ministry of Health.

RNZ

April 17, 2023

‘Buckling’ NHS fails to treat 250,000 children with mental health problems | Mental health

A quarter of a million children in the UK with mental health problems have been denied help by the NHS as it struggles to manage surging case loads against a backdrop of a crisis in child mental health.

Some NHS trusts are failing to offer treatment to 60{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of those referred by GPs, the research based on freedom of information request responses has found.

The research carried out by the House magazine and shared with the Guardian also revealed a postcode lottery, with spending per child four times higher in some parts of the country than others, while average waits for a first appointment vary by trust from 10 days to three years.

In 2021-22, trusts were forced to raise the threshold at which they would offer support to tackle backlogs, which resulted in hundreds of thousands of children being turned away or abandoning treatment after long waits.

The total represents 32{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of all referrals, up from a quarter the previous year, according to the FoI requests sent to 70 UK trusts and boards providing children and adolescent mental health services (CAMHS).

Previous studies have shown that many of the NHS’s 54 mental health trusts in England have raised the threshold of how ill under-18s have to be before they get treatment, in response to the major and ongoing increase in demand for care, which Covid has exacerbated.

That has sparked complaints from the troubled young people affected, their families and GPs who have referred to Camhs that even under-18s who are seriously unwell and have self-harmed or considered suicide are being denied care because they are deemed not ill enough. Mental health services are also struggling with major shortages of psychiatrists and specialist nurses.

Former children’s commissioner Anne Longfield said long waits are resulting in only the worst crises being prioritised. She has heard repeated stories of children who had attempted suicide failing to be offered support because they did not meet a threshold of multiple attempts. “First there is a judgment of whether they actually meant it,” she said, adding: “the threshold is so high because the system is buckling. It was struggling pre-Covid but the pandemic poured rocket fuel on it.”

Olly Parker, head of external affairs at YoungMinds, said the FoI findings showed a “system is in total shutdown” with “no clear government plan to rescue it”, after the 10-year mental health plan was scrapped.

“In the meantime, young people are self-harming and attempting suicide as they wait months and even years for help after being referred by doctors,” he said. “This is not children saying ‘I’m unhappy.’ They are ill, they are desperate and they need urgent help.”

Average waiting lists rose by two-thirds over two years in England, meaning children are waiting on average 21 weeks for a first appointment in England, although the figure drops to just three weeks in Wales. Only 12{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of the trusts which responded to the FoI have met a four-week government target for first appointments.

Almost three-quarters of the English trusts surveyed said they had at least one young person who had been waiting at least a year to be seen, and two-fifths had someone waiting at least two years. The longest wait was 217 weeks, with the average longest wait at all trusts currently 87 weeks across the UK.

This has been Roanna Brewer’s experience. She has two children, 15 and 11, who have been diagnosed with ADHD and autism, and have other mental health problems including self-harm. She has spent more than four years on a CAMHS waiting list for her son, who is still waiting for his formal ADHD assessment, while her daughter has only been offered online group therapy, which is inappropriate for her.

“No parent wants to do what I’ve done, which is lie on the floor of my child’s bedroom every night because they are so terrified and so anxious. They’ve been traumatised enough,” she said.

She has had to take her children out of school due to the lack of support, and despite being a low earner has spent thousands of pounds on private doctors, who have prescribed her children SSRIs.

skip past newsletter promotion

She believes that CAMHS lumps all her daughter’s mental health problems under the umbrella of autism, which has made it hard to get targeted support, despite promises from before the pandemic of a new funded neurodiversity pathway at the trust which would speed up progress through the waiting list. “We still haven’t seen anyone,” she said.

The figures are echoed in a recent report from the children’s commissioner for England, which warned that too many children are being seen in crisis and hospitalised, which earlier intervention could have prevented.

Dame Rachel de Souza, the children’s commissioner, said children’s mental health was a “key pillar” of her work. “I am particularly concerned to see such a surge in demand for help in my recent research. We’re seeing waiting times increase for the first time in years, and evidence of an increasing postcode lottery for children referred for treatment.”

She urged the government to roll out mental health support teams in every school by the end of 2025, and for any mental health investment to target children. “It is vital that this support is available – without it, too many children may end up in crisis.”

Responding to the FoI findings, a Department of Health and Social Care spokesperson said: “We’re determined to do everything we can to support children and young people with their mental health, no matter their background or location.

“Support in school is vital and that’s why we are increasing the number of school mental health teams to almost 400 by April 2023, providing support to 3 million children and young people.

“We’re also working closely with NHS England to introduce new access and waiting time standards for mental health services, ensuring quicker access to high-quality care across the country.”

April 14, 2023

These Doctors Fought the Federal Bureau of Narcotics to Treat Addiction–With Drugs

After years of disappointing results in her quest to treat heroin addiction, Marie Nyswander was more than ready to try something new. When she met a prominent doctor at the prestigious Rockefeller Institute, now the Rockefeller University, the two embarked on an experiment that would define both of their careers and revolutionize the treatment of addiction for decades to come. But not everyone was happy about it.

[New to this season of the Lost Women of Science? Listen to Episode One here first and then to Episode Two.]

EPISODE TRANSCRIPT

The Lost Women of Science podcast is made for the ear. We aim to make our transcripts as accurate as possible, but some errors may have occurred nonetheless. In addition, important aspects of speech, like tone and emphasis, may not be fully captured, so we recommend listening to episodes, rather than reading transcripts, when possible.

—-

KATIE HAFNER: Hey, this is the third episode in our series about Marie Nyswander. We want to remind you that there will be some adult content and some archival audio that includes pretty outdated language about drug addiction.

CAROL SUTTON LEWIS: In the early 1960s, a doctor named Vincent Dole commuted to work every day from Rye, a wealthy suburb north of New York City, to his office on Manhattan’s Upper East Side.

Life had gone well for Vince up to this point. He was born to a rich family in Chicago, went to Stanford, then Harvard Medical School, and now he was working at the prestigious Rockefeller Institute, specializing in obesity and metabolism. Vincent Dole was a big name in his field.

KATIE HAFNER: But his work had grown unfulfilling. He found himself going to the same conferences, meeting the same people over and over, and then there were his patients. In 1982, he told the historian David Courtwright, he’d help them lose weight, but then-

VINCENT DOLE: Invariably in a short time when you kind of relax the routine, they would return to just what they had before. In other words, they were like a thermostat set at a certain weight.

KATIE HAFNER: And often, it was sheer vanity that brought them to his office.

VINCENT DOLE: Ladies would come in and announce they wanted to lose weight or move it around to different locations, and uh, I just figured that I was being kind of utilized on a cosmetic basis. It really didn’t necessarily make medical sense.

KATIE HAFNER: Vince wasn’t just put off by the ladies who expected him to help them slim down. He was bored. And he might have stayed in his comfortable, boring bubble if it weren’t for a quirk of his daily commute. He’d get off the commuter train from Westchester at 125th Street, and then, he’d walk a few blocks through East Harlem to another train that would take him to Rockefeller. And that walk? It was eye-opening.

VINCENT DOLE: I kind of had this sense of commuting between two highly privileged oases through a truly epidemic sea of misery.

KATIE HAFNER: The epidemic was heroin addiction. As we discussed in the last episode, in the late 50s and early 1960s, East Harlem was particularly hard hit by heroin addiction, and the problem was growing.

And if he hadn’t changed trains, he might have never given this much thought—maybe just a glance out the window, forgotten by the time he got to work, like thousands of other commuters. But during that walk, Vince was forced to actually see what was happening in his city.

VINCENT DOLE: And I began to realize that nobody in my community of scientists or people in Rye had any concept of that world, even though the place was right in New York. And we were living in, essentially, living in the midst of an epidemic and ignoring it.

CAROL SUTTON LEWIS: Now, addiction was far outside of Vince’s specialty. But, he thought about what he did know, which was metabolism, and over time, an idea started forming. What if the desire for drugs had something in common with the desire for food? Many people had assumed that obesity was just the result of overeating, but several studies had found that there are people who gain weight without eating any more than other people, and their bodies expended less energy doing the same things. And Vince thought something about their metabolic state could also result in greater cravings for food.

What if something similar was going on here? Something about the metabolism of a person addicted to drugs that made their bodies crave drugs in a way that other people’s didn’t?

Now, here was a proper research puzzle, an opportunity to dive into relatively open scientific territory, an opportunity just waiting for someone to seize it. And maybe that person could be him. Maybe Vincent Dole, famed obesity expert, could even stop an epidemic. All he needed was to actually learn something about addiction.

CAROL SUTTON LEWIS: This is Lost Women of Science. I’m Carol Sutton Lewis.

KATIE HAFNER: And I’m Katie Hafner. This season, the Doctor and the Fix: how Marie Nyswander changed the landscape of addiction. And in today’s episode—an unlikely breakthrough.

EMILY DUFTON: Dole was very high level.

CAROL SUTTON LEWIS: That’s Emily Dufton, writer and drug historian.

EMILY DUFTON: I remember interviewing someone who said they really believed that if Dole had stayed with his work on obesity and metabolism, he would’ve been awarded a Nobel Prize. Like, that’s how well respected this work was, so for him to drop it and be like, mm-mm, heroin addiction—that’s the kind of stakes he was playing with.

CAROL SUTTON LEWIS: Vince was thinking about wading into a field where he had no experience. But even though he was very new to addiction, hadn’t done any of his own research, Vince had connections. And one day he was chatting with one of those connections when an opportunity landed in his lap.

The connection was Lew Thomas. Lewis Thomas was the chairman of the New York City Health Department’s Committee on Narcotics. And on that day, Vince was telling Lew about his new interest in addiction, and said, you know, isn’t it a shame there isn’t more good research in the field? And as Vincent tells it, that’s when Lew essentially handed him the keys to the kingdom.

VINCENT DOLE: He said, well, that’s a great thing. He says, I’m just gonna go off on a sabbatical to France, and I haven’t seen much come out of this committee. Why don’t you become the chairman of it? I said, all right, I’ll do it.

CAROL SUTTON LEWIS: And that was it.

KATIE HAFNER: Okay. I just need to interrupt for one sec and say, wait a minute, are you kidding me? And maybe this is because so little was known about addiction or he was so well connected, but he gets to just become the chairman of some committee on narcotics, knowing absolutely nothing about narcotics? And yet you’ve got Marie Nyswander having put in all this time — I mean, she’s, like, totally steeped in it. She’s published an entire book on addiction.

CAROL SUTTON LEWIS: Even more to your point, this shows you how much they cared about committees on addiction if they’re gonna put a guy in charge who has absolutely no background whatsoever. I mean, there was Dr. Marie Nyswander, I’m sure there were other people who were actually focused on it, but to just, to hand this guy the chairmanship because he was his bud?

KATIE HAFNER: Yeah, well it was a man’s world.

CAROL SUTTON LEWIS: Yep, he gets to stroll right in and he’s put in charge, but at least Vince knew enough to know that he had a lot to learn.

EMILY DUFTON: So he started reading about addiction on his own, just kind of giving himself like the survey of the available literature ‘cause he had never taken a class on addiction. He went to Harvard Medical, no one talked about it. He had no instruction in it whatsoever. There are no conversations about it at Rockefeller. So he began kind of teaching himself and he came across, uh, Marie’s article, and he also came across her book.

CAROL SUTTON LEWIS: In 1956, a few years before Marie published The Power of Sexual Surrender, she’d published a book about addiction called The Drug Addict as a Patient. In this book, Marie efficiently summarized everything she’d learned about addiction—the effect of drugs on the body, methods for easing withdrawal, the history of criminalization in the United States, and some of the theories of addiction from the day.

But most importantly, she argued that addiction was a sickness, not a criminal matter, and that punishing people or coercing them into treatment just didn’t work. Vince liked what he read. Years later he told David Courtwright that Marie Nyswander was the only person who made any sense to him. And he saw in her, not just an expert to consult, but a potential collaborator too. So, sometime in late 1962 or early 1963, Vince gave her a call. And he reached a very tired and frustrated Marie.

MARIE NYSWANDER: By that time, I had exhausted every psychiatric and psychological treatment modality that there was. You name it, hypnosis, group therapy, moving patients around the world.

CAROL SUTTON LEWIS: Almost seven years had passed since Marie had published her book on addiction. Professionally, she was doing well. She still had her private practice on Park Avenue, and an appointment as an assistant professor at New York Medical College. But all those years of treating addiction, they’d worn her down.

EMILY DUFTON: She’s been banging her head against the wall for years trying to, you know, help her patients get better and instead they’re dying. And so Vincent Dole says, you know, hey, come talk to me. I’ve got, um, the backing of Rockefeller University with the prestige and, uh, respectability that that offers. And I’ve got a whole lot of money from the City of New York to try to figure out how to solve addiction. Do you wanna come help me? Do you wanna become a Rockefeller University employee and help me try to solve addiction and we’ve got the money to do it? And she’s like, yes, I think that sounds like a really great idea. Because who wouldn’t?

KATIE HAFNER: And Vince was just as thrilled to work with Marie. Vince’s reaction to Marie would be echoed by others through the years. There was her charisma, for one thing, but also her straight up compassion for her patients, her determination to help them. While we’ve been working on this season, we’ve seen and heard this phrase over and over and over again: she saw her patients – from the outside to deep within.

VINCENT DOLE: She impressed me as a very intense and intelligent, uh, person who was working under absolutely hopeless disadvantages of just administratively ‘cause she was all alone with a good heart and a lot of spirit, uh, trying to fight the entire establishment up and down the line.

KATIE HAFNER: And Marie clearly saw something deep in Vince. From the beginning, let’s just say, they had chemistry. Though not everyone was happy about it. In particular, Marie’s husband, Leonard Wallace Robinson. Carol, remember how Leonard wrote that book we talked about earlier called The Man Who Loved Beauty all about his beloved?

CAROL SUTTON LEWIS: Mm-hmm.

KATIE HAFNER: Yeah. Well, ha- have you read it by the way?

CAROL SUTTON LEWIS: No.

KATIE HAFNER: Oh, okay. Let me just tell you. A fictionalized Vince features heavily in it. In the book, Vincent Dole becomes “Thurman Cantwell,” a New York physician who recruits “Elizabeth” aka Marie, who is also the Beauty in the book, to help him on his quest to find a treatment for alcoholism.

After “Thurman” invites “Elizabeth” to join the research team, Elizabeth is quote “glistening with excitement” – yes, you heard that right, glistening.

And clearly, Leonard is not a fan of the Vince slash Thurman character, so she’s Beauty, and Thurman is Beast. And he’s Beast for much of the book. Leonard’s descriptions of this man, Vince slash Thurman slash Beast, they’re not flattering. He describes him as slightly “cross-eyed” with a, shall we say, confusing body: “6 feet tall”, “a boxer’s nose”, and a curiously “long head, like an ant.” Little to no bedside manner with his patients. And unlike the literary Leonard, Thurman is super clumsy with words, but worst of all, Leonard writes that this man is a bore.

Again, I’ll stress, this is a fictional account. And perhaps a wishful one from a husband watching his wife get a little too glistening about a whole new world that he just wasn’t a part of.

CAROL SUTTON LEWIS: Mm-hmm. So back to the non-fictional account. Marie was officially hired in January 1964. And that same month, Vince brought another member onto the team – a second-year medical resident named Mary Jeanne Kreek.

MARY JEANNE KREEK: Now, you should ask me what it was like when I arrived at Rockefeller in 1964.

CAROL SUTTON LEWIS: In this oral history interview from 2017, a few years before she died, Mary Jeanne had a habit of acting as both interviewee and interviewer. And after posing this question to herself, she proceeded immediately to answer.

MARY JEANNE KREEK: Well, it was wonderful. There was a paucity of women to put it mildly. I was told by Professor Dole, whom I liked very much at the interviews, but I was told to put on a white dress.

KATIE HAFNER: A white dress.

CAROL SUTTON LEWIS: Yep, apparently, that was what women working at Rockefeller wore back then. There was a dress code. Women technicians wore white dresses, though doctors wore lab coats, which is what Mary Jeanne was, so it’s not clear why she was asked to wear the dress.

MARY JEANNE KREEK: I said no, and I was told to go downstairs in Founder’s to the ladies dining room where everyone had on white dresses. And I said, no and no. And as our current president, Rick Lifton, said when he first met me last September, he said, I hope you said ‘blank no.’ And I said, no, I didn’t have the blank in there, Rick, because I’d been taught not to at that point in my life. Now I would had the blank in there, but I just said no and no.

CAROL SUTTON LEWIS: So Mary Jeanne went on wearing her regular clothes. And fortunately, it turns out women could still do research in those.

Okay, that’s our research trio – Marie, Vince and Mary Jeanne. As Mary Jeanne explained it, she was the clinician on the team, meaning she did things like observing reactions and monitoring side effects.

Marie was the psychiatrist, the one who had access to patients and was most familiar with the behavior and psychology of people with addiction.

And Vince did most of the planning and research design, plotting what the experiments would look like

KATIE HAFNER: They started by going all over town, interviewing people with addictions. And pretty soon, it was clear they were about to wander way off script and try something very unorthodox, at least for the United States at the time: abandon the goal of abstinence.

MARY JEANNE KREEK: Marie and Vince and I used to have these think tanks after talking with patients and we’d hear the story – do you like heroin? Not really. You have to take more and more of it. You get high the highest 10 minutes, 20 minutes at most. Then, you’re okay for about an hour or two. If you take too much, you’re sleepy, nodding out. And then you go into withdrawal and you have to do this four to six times a day. It’s just terrible. But I don’t feel normal when I come off it. When they send me to jail and I don’t have any or put in a drug-free environment, I don’t feel normal. It was not that I can’t get high without it. Very important difference. It’s I don’t feel normal without it.

CAROL SUTTON LEWIS: It started to sound like a physical condition, rather than a psychological one. The way these patients described it, addiction wasn’t really about chasing the pleasure of a high. They were craving something they felt like they couldn’t function without, almost like some kind of deficiency.

KATIE HAFNER: Vince had actually been thinking about this for a while, and came up with what he would later call the “metabolic theory” of addiction to explain it. The idea was this: there’s something in the biochemistry of an addicted person that makes them crave drugs. Instead of some kind of personality defect, maybe a person with addiction has a “neurological susceptibility” to begin with, and after repeated drug use their neurons undergo metabolic changes—though what exactly those changes are, Vince couldn’t say at the time.

It was more of a vague concept than a properly worked out theory, but it pointed them in a particular direction—because if the problem was a biochemical imbalance, then the treatment probably needed to be pharmacological. The analogy the Rockefeller team and others would come back to over and over was diabetes. A person with diabetes needs insulin. The body can’t function without it, and a person with an opioid addiction might just need opioids. Indefinitely.

And from that perspective, the abstinence approach to drugs was just never going to work. But then what was the alternative?

CAROL SUTTON LEWIS: After years of trying everything and failing, Marie was very ready to try something new. And she wondered, what would happen if you just gave people drugs? Well, that was actually a question you could answer empirically.

Coming up: the experiment.

==== BREAK ====

CAROL SUTTON LEWIS: In the early 1960s, as the Rockefeller trio set out to run their first experiments, they dared to ask a question that was controversial then and is controversial now: what’s so wrong with heroin?

VINCENT DOLE: That was one of the first questions I asked, I said, gee, I don’t see what’s so bad about this if it’s not demonstrably, uh, killing these people. And surely, taking the junk on the street is killing them, and is killing society through the crime it’s generated by these high prices that they have to pay, and it’s a robbery. I said, I don’t see really what’s all the talk’s about. Let ’em have it.

CAROL SUTTON LEWIS: Yeah. I’m sure some of you are having strong reactions here. I want to be clear, heroin is definitely not good for you. Tens of thousands of people die each year from heroin and other opioid overdoses in the United States. Although fentanyl, a synthetic opioid, has dramatically overtaken heroin, heroin still kills thousands each year. It depresses your respiratory drive—and if you take too much, your breathing grows slower and shallower until you stop breathing altogether.

KATIE HAFNER: As Vince saw it, what compounded the danger was the criminalization, the lengths people were forced to go to get heroin. Add to that the unreliable quality of street drugs. Maybe, if drugs were administered in a safe and legal controlled setting—with careful dosing and without contamination—then those drugs didn’t have to be so dangerous?

And this is what we call maintenance: the idea that you can keep a person with a drug addiction comfortable and able to function well—or at least better—by keeping them on drugs. Under maintenance, patients wouldn’t have to deal with repeated withdrawal symptoms or the incessant cravings. They wouldn’t have to break the law to get drugs. They wouldn’t have to worry about what was actually in the drugs once they got them. And they could focus on other things. It was actually a well-established approach in the U.K. at the time.

As Marie tells it, her initial reaction to this idea was alarm. Once, she was meeting with a prominent medical writer named Blake Cabot. They’re sitting there talking and he says to Marie, did you ever stop to think what’s so wrong with giving addicts drugs?

MARIE NYSWANDER: And I almost fainted, and I almost threw ’em out of the house. And I left the room and it was just, I mean, it was like saying a prejudiced statement or something, you know. I just- I had to get hold of myself. So, I- obviously some kind of an emotional leap was made there. (Mm-hmm) And, uh, then I began picking up different information as you always do, you know, you exclude information that doesn’t fit in with your idea. (Mm-hmm)

KATIE HAFNER: And Carol here, I wanna talk about this whole concept. In fact, David Courtwright wrote a paper on it called “The Prepared Mind.” And that is what we see a lot in science, is it’s the prepared mind that leads you to discovery.

So after years of trying and failing with these other methods, she was ready to try something new and the team of Mary Jean and Marie and Vince decided to start with the basics – find out what drugs actually do to a person. Which meant bringing people to the very straight-laced Rockefeller Institute and giving them drugs.

MARY JEANNE KREEK: And think about that. This is a pristine environment, beautiful gardens, quiet scientists, and a lovely little hospital that was created in early 1900s. And we wanted to bring in active heroin addicts, oh my goodness.

KATIE HAFNER: Not only would it raise some eyebrows, but it was questionable on legal ground, or at least it was according to the Federal Bureau of Narcotics. They believed it was illegal under the Harrison Narcotic Act of 1914, that big federal anti-drug law that restricted the sale and prescription of narcotics.

CAROL SUTTON LEWIS: And the Bureau could be scary. For three decades, it was headed by a man named Harry Anslinger, one of the most powerful men in Washington and a larger than life figure in American history. The way Marie described him, he was like a cartoon villain.

MARIE NYSWANDER: Like a movie character of a despot [laughs]. He was kind of baldish, with a very thick neck, and very ruddy complexion, and didn’t smile very much.

CAROL SUTTON LEWIS: Under Anslinger, the Bureau arrested doctors for overprescribing opiates—and the Bureau decided what counted as overprescribing. Harry Anslinger finally retired in 1962, but that didn’t stop him from giving this interview to a Baltimore TV station a year later.

HARRY ANSLINGER: The average addict walking the streets of the cities in this country is just like a leper. He spreads the disease. Uh, he must be taken out of circulation.

CAROL SUTTON LEWIS: “Taken out of circulation.” It’s chilling.

KATIE HAFNER: And this is the context that Marie and her team are operating in. Marie had been having her own skirmishes with the Bureau for quite a few years at that point. She’d caught its attention because of her earlier work with addiction patients—agents had started coming to her office and meetings uninvited. What she and her new collaborators were planning was bold, to say the least, and they did not want any trouble. Luckily, the team had Vincent Dole, who tended to get his way.

VINCENT DOLE: I asked first of all, uh, that Bronk was president of Rockefeller, whether this would cause him any problems if I got into such a politically controversial field, and I said that this problem is too hot for any doctor or institution of the country to handle so far as I know. And he said, if that’s so, he said, then it’s our job to do it. And he didn’t ever raise any questions about any of the pressures that were on me and I suppose that he probably through his authority deflected.

KATIE HAFNER: So that was easy. And they had legal support too. Rockefeller’s lawyers concluded that contrary to what the Bureau was saying, the law was actually on the doctors’ side, that the Harrison Narcotic Act didn’t actually prohibit them from prescribing opioids if they thought it was necessary for treatment or clinical research. And yet, for decades, the Bureau had been intimidating and arresting physicians until they tried it with the esteemed Vincent Dole.

VINCENT DOLE: It wasn’t long before The Bureau of Narcotics sent an agent out who came in the most peremptory, arrogant way and hammered the table and says, you’re breaking the law. And I said, well, I have been looking into that and as far as I understand, I’m not. And they said, well, you are, and if you don’t stop, we’ll uh, put you outta business. So I said, well, then maybe that’s the proper thing to do. I said, the thing you ought to do, given the way you understand it, is to sue me.

KATIE HAFNER: It was as though he’d said a magic word– Vince completely disarmed the agent.

VINCENT DOLE: He abruptly left the discussion, and said that he would have to discuss it further with his superiors. This type of an interaction was repeated once or twice in one form or another until they became persuaded that there really was not an easy way to sort of force us out by threats.

CAROL SUTTON LEWIS: And that was that the team could get to work. They just needed research subjects. They started with two men, one, a 30-something Italian-American, and the other, a 20-something Irish-American, both addicted to heroin.

MARIE NYSWANDER: Anyway, brought in two [laughs] quiet and weak—well, not so weak—addicts, put them on narcotics, and I was allowed to put them on any narcotics I wanted, any amount. We just tried to keep them comfortable.

KATIE HAFNER: The plan was to have these patients live at Rockefeller, take various drugs, and allow the doctors to observe the effects. And as soon as the trials started, observing them became a full time job for the team. Vince and Marie and Mary Jeanne started to spend a lot of time at the clinic together, especially Marie and Vince.

In Leonard’s fictional account, he describes how Marie/Elizabeth’s social life began to shift. Again, I asked my husband, Bob, to do a reading. He’s gotten awfully confident with his reads.

BOB AS LEONARD: Her move to bio shook up our lives considerably. She had to work harder than I’d ever seen her work. She worked very late at night now, and our social life shifted dramatically. Her friends had become mine, and vice-versa – painters, poets, teachers, mainly. But now, scientists were added.

KATIE HAFNER (off-mic): Nice, nice.

BOB: Yeah, that’s pretty, that’s, that’s pretty good.

KATIE HAFNER: So, yes, she was drifting away from Leonard and into this new role, into this world of hard science and deeper into the world of her patients. Her old patients in Harlem had walked in and out of her life, but now her patients were research subjects in her full-time care.

MARIE NYSWANDER: I just tried to keep two patients comfortable on narcotics.

KATIE HAFNER: So what drugs would keep the patients comfortable? As Marie told David Courtwright years later, the team tried everything they could think of—morphine, dilaudid, cough medicine, even regular doses of heroin itself! But nothing was working.

MARIE NYSWANDER: The patients were not happy. They were looking at their watches and going in and out of withdrawal, comfortable for maybe an hour. Never got dressed. Never had any goals other than waiting for the next shot. The dosage went up and up, and this was not a program designed to make them high, but simply to keep them comfortable. I could not make them function. There was no way I could make them function. And so after this went on for several months and the dosage was so high, it was clear it was a failure.

KATIE HAFNER: It seemed to Marie that they’d exhausted everything, but there was one drug the team hadn’t tried – methadone hydrochloride.

CAROL SUTTON LEWIS: Methadone had actually been around for a while by then. It had come to the US from post-war Germany almost two decades earlier.

DAVID COURTWRIGHT: Well, it’s a fascinating story. When the Americans start going through all of this technical and scientific information that they’ve hauled away from Germany, they discover, oh, hey, the Germans have got this new synthetic drug. And sure enough the tests quickly confirmed that it was morphine-like in its effect.

CAROL SUTTON LEWIS: It had been developed by I.G. Farben, a German company that had been so integral to the Nazi regime, it was sometimes called “the devil’s chemist.” I.G. Farben had used tens of thousands of slave laborers during the war, many from Auschwitz, to work in its factories. It manufactured Zyklon B – the poison used in the gas chambers.

CAROL SUTTON LEWIS: They also manufactured methadone, which the Germans called amidon. Like all opioids, it’s a powerful painkiller, much more powerful than morphine, as it would turn out.

DAVID COURTWRIGHT: And the implications of this, uh, quickly became apparent, both in the medical community and to the old Federal Bureau of Narcotics.

Um, the medical community saw it as a potentially valuable synthetic opioid analgesic, and the Bureau of Narcotics saw it as that, but also as a drug that presented, um, a threat of addiction or diversion and which needed to be regulated like other narcotic drugs.

So there was a bit of legal maneuvering, but ultimately the Bureau prevailed and got it classified as a narcotic drug like morphine.

CAROL SUTTON LEWIS: At Lexington, the Narcotic Farm in Kentucky, the research center had also been interested in methadone, and they’d run experiments on patients. This was close to—and maybe even at the same time—that Marie was there.

DAVID COURTWRIGHT: And sure enough, it satisfied their craving. It prevented them from going into withdrawal.

CAROL SUTTON LEWIS: The problem, at least according to an early study, was that some patients seemed to like methadone a little too much. When the researchers gave it to people addicted to morphine, they heard comments like: “That is great stuff.” “I wouldn’t have believed it possible for a synthetic drug to be so like morphine.” “Can you get it outside?” And the researchers concluded this drug was risky — it would surely be abused if it became freely available. And after that, methadone fell out of prominence.

KATIE HAFNER: So back in 1964, the Rockefeller team had been trying everything they could think of, and nothing was working. Their patients were getting high doses of opioids, but they were still irritable, distracted, and dissatisfied. And then, the doctors decide to try methadone. Since their patients had been on high doses of other opioids, they put them on equivalent high doses of methadone – presumably to avoid harsh withdrawal symptoms.

Now, when methadone was used for detox, the dose was something like 15 to 25 milligrams, maybe 40 milligrams tops. But to match the high levels of opioids they were already giving these two men, the team would have to up the methadone dose by a lot.

MARIE NYSWANDER: These were very large amounts in 90 milligrams, 80, 90, 100 milligrams. We were very scared of that amount.

KATIE HAFNER: But they went ahead with it. And the next day or the day after, there were two young men unlike anything that they had previously seen. The patients were dressed, their color was good. They seemed almost too good.

MARIE NYSWANDER: I didn’t believe it. I had been around too long and seen too many miracles which turned out not to work. So I think, in a way, Mary Jeanne Kreek, who had no such past failure experiences, noticed and believed it at first.

CAROL SUTTON LEWIS: Marie was reluctant to get her hopes up. But Mary Jeanne, she could see something significant was happening. And Vince noticed it too. He had gotten in the habit of chatting with the patients every day for about two or three hours. Just casual conversations to get to know them better. And when they started taking methadone, he noticed a shift.

VINCENT DOLE: Our conversations were moving into orbits, like, uh, baseball and politics and, and more general topics that you’re likely to come into rather than endlessly, endlessly recalling, uh, drug experiences.

CAROL SUTTON LEWIS: The patients seemed interested in their lives again. They were even asking to go back to school to finish their education. The Rockefeller doctors hadn’t seen this with anything else they’d tried.

KATIE HAFNER: So at this point, methadone looked promising. But so far, these patients had been living full time in this controlled hospital environment. Yes, this treatment seemed to have changed the patients. But what would happen if they actually went out into the world? There was only one way to find out. But, Marie was nervous.

MARIE NYSWANDER: I didn’t know how far I wanted to trust this. Uh, I could see now they said they didn’t want any drugs. Okay. But now when they’re out in the street, is this methadone gonna carry when they’re out in the street and then they see drug addicts? They still gonna come home without a shot, they’d come back?

KATIE HAFNER: Living outside the hospital, encountering all the hardships and temptations of the city, that was the real test. And it was about to begin. The patients would still sleep at the hospital, but during the day, they’d be free to go where they pleased. And one day, off they went.

MARIE NYSWANDER: I’d sit here at night waiting for them to come back, in total terror every night, and I wouldn’t go home until after they got back. And I couldn’t tell them because I didn’t want that pressure on them.

KATIE HAFNER: But they did come back that first day. And the second, and the day after that. Over and over, the patients came back. One time, they told Marie this story, they told her that, yeah, we saw people buying drugs across the street, but we didn’t feel tempted.

With methadone, they weren’t craving heroin. What were they craving instead on that day? Ice cream. Yep, instead of buying heroin, her patients told her they’d gone and bought ice cream cones.

CAROL SUTTON LEWIS: These results were astounding, but was it just a fluke? Next, the Rockefeller doctors expanded the study of methadone to six more patients, a varied group with different backgrounds, and different levels of education. And once again, same results.

MARIE NYSWANDER: They were all looking wonderful and going to school. And, and you never saw six such nice, attractive, uh, young men. And we had some narcotic agents up to meet them and talk to them. These days, we were inviting people in. So there were, I think two or three narcotic agents who came up and we were talking about narcotics, and then we introduced ’em to patients and said, well, here’s some drug addicts. Would you like to talk with them? And they said, oh, these aren’t addicts.

CAROL SUTTON LEWIS: It looked like Marie and her team had found a treatment plan that just might work. But had they?

Next time: Marie and Vincent share what they found with the world—but not everyone likes it.

KATIE HAFNER: The Lost Women of Science podcast is hosted by me, Katie Hafner-

CAROL SUTTON LEWIS: -and me, Carol Sutton Lewis. This episode was produced by Zoe Kurland, Nora Mathison and Elah Feder, our senior producer, with help from Alexa Lim, Emma Sullivan, Mackenzie Tatananni and Dominique Janee.

KATIE HAFNER: We had fact checking help from Danya AbdelHameid. All of our music is by Lizzy Younan. D Peterschmidt mixed and designed the sound for this episode.

CAROL SUTTON LEWIS: Once again, a big thank you to David Courtwright who shared his oral history collection with us. It’s called Addicts Who Survived, and includes the interviews you heard with Marie Nyswander and Vincent Dole and much more.

KATIE HAFNER: I want to thank my co-executive producer at Lost Women of Science, Amy Scharf. We are funded in part by the Alfred P. Sloan Foundation, and Schmidt Futures. Our podcast is distributed by PRX and published in partnership with Scientific American.

CAROL SUTTON LEWIS: For show notes and more about the whole team that makes this show happen, visit lost women of science dot org. Finally, if you like what you heard, please tell one person you know! Today! It really helps the show!

KATIE HAFNER: Yeah. You tell one person and then five people will know.

CAROL SUTTON LEWIS: [laughing] What? Katie’s lost it.

KATIE HAFNER: See you next week!

March 3, 2023

Safe injection sites don’t treat addiction, they enable it

Have you ever cleaned blood off of an intoxicated loved one’s confront? How about vomit? Have you ever experienced a stability method installed mainly because a loved one’s addiction threatened your safety? Addiction doesn’t just harm the daily life of the addict it is a wrecking ball swinging by means of people, friendships, and communities.

How do we best help a particular person in the thrall of habit? Where is the line involving assisting and enabling? What does generating a secure place for risky, destructive habits do to a community? What does the normalization of dangerous and possibly lethal behavior converse to people tempted to have interaction in it?

These are the queries Colorado lawmakers need to look at when Household Monthly bill 1202 is read on the floor of the Colorado Dwelling of Reps. The bill would allow for neighborhood governments to open up supervised injection web-sites (SIS), also named secure usage sites, in which folks could entry absolutely free drug paraphernalia and use illicit prescription drugs such as heroin and fentanyl in the existence of health-related staff with out fear of prosecution.

The laudable function of this monthly bill is to cut down the incidence of drug overdose and the unfold of condition from dirty needles. Denver would most likely be initially in line to open such a facility considering that the metropolis council handed an ordinance authorizing a lawful injection site pending condition acceptance.

Despite the fact that safe and sound injection internet sites have existed in 10 other nations around the world, Denver would be part of New York City as the initial in The us to experiment with legalized opioid use. While some web-sites have been all over for decades, investigate on the efficacy of SIS and community results is inconclusive, according to Stanford University dependancy researcher Keith Humphreys.

While some studies recommend that authorized usage web pages lessen overdose fatalities and do not maximize criminal behavior in the neighborhood in which they are found, he explained to NPR, “Nobody should be on the lookout at this literature building assured conclusions in either course.”

Several drug policy industry experts and previous federal drug officers observe the methodological weaknesses in the study. They query whether or not injection internet sites save lives or basically delay dying from untreated drug habit. Lots of SIS users proceed to inject medicine when not on web site and hence continue to be at risk of overdose. Supervised injection web pages do not handle drug habit in some techniques, they enable it and increase the possibility that the human being will at some point put up with a lethal overdose.

These critics notice that Vancouver, Canada, where by this kind of websites have existed for many years, has skilled much more drug working, homelessness, violent criminal offense, and death in locations the place this sort of services exist. Denver households and small business proprietors impacted by the ongoing existence of squalid vagrant camps have just about every explanation to be skeptical of getting an injection web-site in their community.

Lastly, what concept does legalizing drug use mail to teenagers and people tempted to use? The strategy of a “safe injection site” normalizes and destigmatizes drug use. This is risky, in particular at a time when Denver drug experts are reporting they are observing more kids with addictions than in the past.

Colorado legalized and commercialized cannabis extra than a ten years ago, and utilization of the drug is greater than the nationwide typical. Final election, a slender majority voted to legalize psychedelic substances ostensibly for mental overall health. Assume an raise in use there.

By contrast, govt agencies actively discourage tobacco use by limiting using tobacco in general public areas, making it possible for insurance coverage providers to demand better premiums, taxing items at high costs, and communicating an unambiguous concept that tobacco kills. Alongside with neighborhood organizations, they have labored to de-normalize a when ubiquitous apply. The share of adult smokers has lessened from 42{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} in 1965 to just 14{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} currently. As a previous nicotine addict, I am grateful.

When people today at a supervised injection web-site can shoot up unlawful medicine but not smoke authorized cigarettes, what information does that ship?

The lawmakers and advocates who are pushing Home Bill 1202 necessarily mean effectively, but if the bill becomes law, the wrecking ball of dependancy will keep on its lethal arc as a result of our communities. It may possibly even decide on up speed.

Krista L. Kafer is a weekly Denver Put up columnist. Observe her on Twitter: @kristakafer

Signal up for Audio Off to get a weekly roundup of our columns, editorials and a lot more.

To ship a letter to the editor about this write-up, submit on the net or look at out our rules for how to post by e mail or mail.

February 28, 2023

Can A.I. Treat Mental Illness?

Ahead of a different individual go to, Maria recalled, “I just felt that one thing seriously negative was going to materialize.” She texted Woebot, which described the strategy of catastrophic pondering. It can be handy to prepare for the worst, Woebot said—but that planning can go far too considerably. “It assisted me identify this detail that I do all the time,” Maria said. She observed Woebot so effective that she begun looking at a human therapist.

Woebot is just one of quite a few successful cellphone-dependent chatbots, some aimed particularly at psychological health and fitness, many others developed to offer entertainment, convenience, or sympathetic discussion. Currently, thousands and thousands of persons speak to applications and apps such as Happify, which encourages people to “break old styles,” and Replika, an “A.I. companion” that is “always on your aspect,” serving as a good friend, a mentor, or even a romantic spouse. The worlds of psychiatry, remedy, laptop or computer science, and purchaser know-how are converging: more and more, we soothe ourselves with our equipment, even though programmers, psychiatrists, and startup founders layout A.I. systems that evaluate medical data and therapy sessions in hopes of diagnosing, dealing with, and even predicting mental illness. In 2021, electronic startups that focussed on mental wellness secured far more than five billion dollars in undertaking capital—more than double that for any other clinical problem.

The scale of financial investment displays the dimension of the trouble. Approximately a single in 5 American adults has a psychological disease. An approximated 1 in 20 has what’s considered a significant psychological illness—major melancholy, bipolar ailment, schizophrenia—that profoundly impairs the skill to stay, operate, or relate to other people. A long time-aged prescription drugs such as Prozac and Xanax, as soon as billed as groundbreaking antidotes to depression and stress, have proved much less successful than several had hoped care stays fragmented, belated, and insufficient and the in excess of-all stress of psychological health issues in the U.S., as calculated by decades lost to disability, looks to have elevated. Suicide premiums have fallen close to the globe since the nineteen-nineties, but in The united states they’ve risen by about a third. Mental-wellness treatment is “a shitstorm,” Thomas Insel, a previous director of the National Institute of Psychological Health, explained to me. “Nobody likes what they get. No person is content with what they give. It’s a complete mess.” Because leaving the N.I.M.H., in 2015, Insel has labored at a string of electronic-mental-well being providers.

The remedy of psychological illness demands creativeness, insight, and empathy—traits that A.I. can only pretend to have. And nevertheless, Eliza, which Weizenbaum named following Eliza Doolittle, the faux-it-till-you-make-it heroine of George Bernard Shaw’s “Pygmalion,” created a therapeutic illusion despite possessing “no memory” and “no processing power,” Christian writes. What may a program like OpenAI’s ChatGPT, which has been skilled on extensive swaths of the composing on the Net, conjure? An algorithm that analyzes patient data has no interior understanding of human beings—but it may well nevertheless discover actual psychiatric issues. Can synthetic minds mend real ones? And what do we stand to acquire, or get rid of, in letting them attempt?

John Pestian, a personal computer scientist who specializes in the evaluation of medical details, 1st started off applying device studying to research mental illness in the two-1000’s, when he joined the college of Cincinnati Children’s Clinic Healthcare Center. In graduate university, he had constructed statistical models to make improvements to care for sufferers undergoing cardiac bypass operation. At Cincinnati Children’s, which operates the greatest pediatric psychiatric facility in the region, he was shocked by how lots of youthful men and women arrived in after attempting to conclusion their individual life. He needed to know regardless of whether pcs could determine out who was at hazard of self-hurt.

Pestian contacted Edwin Shneidman, a medical psychologist who’d established the American Association of Suicidology. Shneidman gave him hundreds of suicide notes that families had shared with him, and Pestian expanded the collection into what he thinks is the world’s major. Through one of our conversations, he confirmed me a observe created by a younger female. On one facet was an offended concept to her boyfriend, and on the other she dealt with her mothers and fathers: “Daddy be sure to hurry home. Mom I’m so worn out. Please forgive me for anything.” Researching the suicide notes, Pestian found designs. The most prevalent statements were not expressions of guilt, sorrow, or anger, but recommendations: make certain your brother repays the funds I lent him the car is virtually out of gasoline watchful, there’s cyanide in the toilet. He and his colleagues fed the notes into a language model—an A.I. method that learns which words and phrases and phrases are inclined to go together—and then examined its capability to recognize suicidal ideation in statements that men and women made. The benefits advised that an algorithm could recognize “the language of suicide.”

Following, Pestian turned to audio recordings taken from individual visits to the hospital’s E.R. With his colleagues, he designed application to examine not just the terms folks spoke but the appears of their speech. The staff uncovered that folks enduring suicidal feelings sighed much more and laughed considerably less than many others. When speaking, they tended to pause lengthier and to shorten their vowels, producing terms fewer intelligible their voices sounded breathier, and they expressed much more anger and much less hope. In the biggest trial of its variety, Pestian’s workforce enrolled hundreds of clients, recorded their speech, and used algorithms to classify them as suicidal, mentally unwell but not suicidal, or neither. About eighty-5 for each cent of the time, his A.I. product came to the very same conclusions as human caregivers—making it likely beneficial for inexperienced, overbooked, or unsure clinicians.

A several several years in the past, Pestian and his colleagues used the algorithm to produce an application, termed SAM, which could be employed by school therapists. They analyzed it in some Cincinnati general public universities. Ben Crotte, then a therapist dealing with center and significant schoolers, was among the initial to attempt it. When inquiring college students for their consent, “I was incredibly clear-cut,” Crotte advised me. “I’d say, This software in essence listens in on our conversation, data it, and compares what you say to what other persons have claimed, to recognize who’s at hazard of hurting or killing on their own.”

A single afternoon, Crotte met with a large-college freshman who was battling with extreme panic. In the course of their conversation, she questioned irrespective of whether she desired to keep on residing. If she was actively suicidal, then Crotte experienced an obligation to tell a supervisor, who could choose additional motion, this kind of as recommending that she be hospitalized. Soon after chatting much more, he resolved that she was not in instant danger—but the A.I. came to the opposite conclusion. “On the a single hand, I assumed, This thing really does work—if you’d just achieved her, you’d be quite anxious,” Crotte said. “But there had been all these items I understood about her that the app did not know.” The woman experienced no heritage of hurting herself, no specific programs to do something, and a supportive spouse and children. I requested Crotte what may well have took place if he experienced been less familiar with the student, or a lot less knowledgeable. “It would surely make me hesitant to just permit her depart my business,” he informed me. “I’d truly feel anxious about the legal responsibility of it. You have this thing telling you another person is significant danger, and you are just going to enable them go?”

Algorithmic psychiatry consists of numerous sensible complexities. The Veterans Well being Administration, a division of the Division of Veterans Affairs, might be the initially significant wellness-care company to confront them. A several times prior to Thanksgiving, 2005, a twenty-two-calendar year-outdated Army expert named Joshua Omvig returned house to Iowa, immediately after an eleven-month deployment in Iraq, demonstrating indicators of post-traumatic anxiety disorder a month afterwards, he died by suicide in his truck. In 2007, Congress handed the Joshua Omvig Veterans Suicide Avoidance Act, the to start with federal legislation to tackle a long-standing epidemic of suicide among the veterans. Its initiatives—a disaster hotline, a marketing campaign to destigmatize mental ailment, necessary teaching for V.A. staff—were no match for the dilemma. Each individual year, thousands of veterans die by suicide—many occasions the selection of soldiers who die in beat. A group that involved John McCarthy, the V.A.’s director of details and surveillance for suicide avoidance, gathered information about V.A. individuals, applying studies to detect possible risk aspects for suicide, these types of as long-term pain, homelessness, and despair. Their results were being shared with V.A. caregivers, but, among this info, the evolution of healthcare investigation, and the sheer quantity of patients’ records, “clinicians in care have been obtaining just overloaded with signals,” McCarthy explained to me.

January 26, 2023

The psychedelic ibogaine can treat addiction. The race is on to cash in | Drugs

Lynn Smith was lying in a bed on the third floor of a beachfront house, unable to move her body from the neck down. A buzzing grew louder in her eardrums; just when she thought she couldn’t take it any more, it stopped. Then the visuals started.

For 22 hours after a nurse administered three pills of a psychedelic called ibogaine, Smith relived the series of events that had led her to this treatment clinic just south of Tijuana, including being ejected from a truck years prior. The accident left her with a crushed skull and prescriptions for the opioids she was addicted to for almost 20 years.

“It was horrific, it was the worst thing in the world, what I saw,” said Smith (whose name has been changed to protect her identity) referring to her experience on ibogaine. Behind closed eyelids, she also witnessed wires in her brain being ripped apart, singed, and pieced back together like a puzzle. Under the watch of a nurse who kept an eye on her vitals, Smith’s body shot straight upright in bed then flopped back down before darting up again – all part of an ibogaine trip.

woman leans over patient in bed with medical equipment nearby — A nurse prepares a guest for ibogaine treatment at the Beond psychedelic retreat center. Photograph: Courtesy Beond

She spent five weeks at the clinic, where, not unlike upscale in-patient substance use disorder treatment centers in the United States, she was offered psychotherapy sessions, acupuncture, and lounge chairs overlooking the beach. But the main attraction was the powerful psychedelic, an experience Smith, now an in-home caretaker in Arizona, believes saved her life. “It’s like I was put back to the day before I ever used a drug,” she said.

A Schedule I substance (the same category as heroin, cannabis and peyote) in the US, ibogaine is a controlled substance with no recognized medical benefits and a high risk of abuse. It is illegal in the US, but in countries such as Costa Rica, Mexico, New Zealand and the Netherlands, it is unregulated, which has allowed clinics to flourish. Starting in the early 2000s, the opioid crisis – in April 2021, annual overdose deaths in the US reached 100,000 for the first time; the Centers for Disease Control and Prevention estimates that nearly 76,000 of these deaths were from opioids – gave way to a booming industry of makeshift ibogaine treatment clinics like the one where Smith was treated, often set up in rented houses located right across the US border.

A simple internet search for ibogaine therapy in Mexico will reveal plenty of options – mostly unregulated, with some existing only on social media. A few are fully accredited medical facilities, others do not include any medical personnel at all and most sit somewhere in between – a local doctor may have a relationship with a provider and clear patients for an ibogaine dose, but may not be present during the treatment. Some are run solely by people who have used ibogaine to get clean and want to help others do the same. They are generally more affordable than traditional rehab clinics in the US (Smith paid $12,000) and offer opioid users another option when rehabilitation and 12-step programs have failed.

photo of the plant with green leaves and yellow fruits — Gabon is one of the few places the plant naturally propagates. Photograph: Biosphoto/Alamy

Over the past decade, ibogaine’s popularity has incentivized poachers to target shrubs in Gabon, one of the few places Tabernanthe iboga, the plant ibogaine is most commonly derived from, naturally propagates. Consumed in small doses, iboga root bark acts as a stimulant, often brewed into palm wine or chewed to curb hunger and fatigue. In larger doses, iboga has powerful psychoactive effects, which have been harnessed for centuries by the Fang, Mitsogo and Punu people of the Congo Basin, as part of the Bwiti religion. The ongoing poaching is depleting natural reserves of iboga in Gabon’s forests and cutting Gabonese people out of an industry that would not exist without their Indigenous knowledge.

The popularity of ibogaine treatment has also caught the interest of researchers and drug developers, posing ethical questions regarding who has a right to profit off of Indigenous knowledge. Psychedelic therapies are expected to grow into a nearly $11bn industry in the next five years. If developed, synthetic drugs derived from the compounds in ibogaine could offer hope for addiction treatment and decrease demand for poached plants. But as researchers continue to untangle the pharmacological potential of ibogaine, and drug companies take an interest, the people of Gabon are grappling with how they will fit into the equation.

Meanwhile, in Mexico, supply is striving to match demand. Tom Feegel is CEO of Beond, an ibogaine therapy provider in Cancun that opened in February of 2022 and is a fully certified Class 1 medical facility credentialed by the federal government of Mexico. It offers holistic treatment to a maximum of 30 people at a time. There is no database that tracks the exact number of people providing ibogaine therapy, but Feegel estimates as many as 150 ibogaine providers are operating worldwide. He estimates only about 10 are correctly certified as accredited medical clinics.

hands over a glass dish full of yellowish powder — Lex Kogan of Envision Recovery uses shredded bark of *Tabernanthe iboga* in Costa Rica. Photograph: Juan Arredondo/Getty Images

“The types of people who have tried every other method of rehabilitation and have had them not work are really desperate and are sometimes willing to compromise their safety and values to get help,” he said. “That’s what allows this wild west methodology to exist.”

Feegel refers to some of the ibogaine clinics as “drive-thru detoxes”. “They use ibogaine to offset or temporarily eliminate the symptoms of withdrawal, largely from opioids, and they are not in the business of healing. It is a psychedelic version of what we call the treatment model, where people have to come back,” he said.

Without proper care people have died, usually from cardiac arrest. This is the worst-case scenario, but Feegel said not giving people important auxiliary care, such as psychotherapy during their stay and continuing support once they return home, is another big failure of many providers.

He vows to raise funds to open a chain ibogaine therapy clinics in Mexico with more comprehensive medical and emotional support during treatment, as well as after care. He also plans to open a second clinic in Cancun next month, with hopes of scaling up to treating 300 people a day.

Curb the risk, make a profit

Using ibogaine as a treatment for substance use disorder has become a primary focus of research, but its legal status and potential health risks have made it difficult for researchers to study its effect on humans.

Ibogaine can strain the kidneys and liver, but deaths are almost always attributed to its effect on the heart. Observational studies have concluded that since ibogaine is a stimulant, it can speed heart rate enough to cause cardiac arrest. That risk is amplified by ibogaine clinics operating largely without regulation and the standards of medical care – such as monitoring heart rate and testing patients for drugs that might interact dangerously with ibogaine – that protect the safety of patients who take it.

Scientists in various parts of the world are working to develop synthetic compounds based on ibogaine that can be turned into pharmaceuticals that provide the same benefits without the risks. David E Olson is co-founder and chief innovation officer of Delix Therapeutics. Its goal is to preserve the anti-addiction effects of natural ibogaine while making it safer and eliminating its psychoactive effect.

“We have a hypothesis that the ultimate change that is most important for the therapeutic effects of the compound are changes in structural neuroplasticity in a part of the brain called the prefrontal cortex,” he said. “A single compound that can work across substance use disorders and can potentially produce very long-lasting effects after a single administration, and that you’re not taking daily … it’s something that is changing the wiring of the brain.”

powders in vials next to roots — Ibogaine can strain the kidneys and liver, but deaths are almost always attributed to its effect on the heart Photograph: Farmer Images/Getty Images

Delix has completed pre-clinical trials and hopes to start human clinical trials in the second half of 2023. In the past year, the FDA has paused clinical trials for other synthetic compounds, including one called 18-MC, over safety concerns.

Olson said that companies should not solely profit off of indigenous plants but argued that synthetic molecules that are unique, though based on ibogaine’s structure, were a different beast. Despite the remaining ethical and scientific questions, he said one thing was clear: ibogaine and the synthetic molecules based on it present a novel opportunity for addiction medicine.

Kurt Rasmussen, chief scientific officer of Delix, said synthetic compounds based on the structure of ibogaine will push addiction treatment further in countries including the US, where ibogaine cannot legally be studied. Synthetic versions also eliminate the need to use root bark in research, which could exacerbate the incentive for poaching. Another way to protect Gabon’s stock of the plant is using an alternative plant altogether. Genís Oña, researcher coordinator at the International Center for Ethnobotanical Education, Research and Service (Iceers) in Spain, is part of a group conducting the world’s first double-blind phase II clinical trial on ibogaine for methadone tapering. They are also exploring an alternative to Tabernanthe iboga.

Other plants contain ibogaine, including one called Voacanga africana. Extracting it takes an extra step, but once that’s done, the final compound is virtually identical to ibogaine from Tabernanthe iboga. The ibogaine used in the novel ICEERS clinical trial is from Voacanga africana.

Psychedelic-focused therapeutic tourism exists around the world and includes plants other than iboga, most notably ayahuasca. But not all psychedelics have the same effect on addiction. Oña said ibogaine was unique in its ability to curb withdrawal when a person is detoxing from pharmacological treatments, such as methadone, for opioid addiction.“There is an instantaneous relief of withdrawal symptoms, which does not happen with ayahuasca, “ said Oña.

With ayahuasca and psychedelics other than ibogaine, the focus is on psychotherapy. The trips can give people insight into the issues that underlie their addictive behaviors and help them use that insight to get sober. Ibogaine is unique. While it does prompt psychological insights similar to those produced by other psychedelics, it is the only one that also has a physical effect that stifles symptoms of opioid withdrawal.

Ayahuasca has been used in Peru as a therapy for substance use disorders, “but it is not providing any pharmacological anti-addictive effect,” said Oña. “The only thing that ayahuasca and iboga have in common is that they are hallucinogens.”

Preparing for an industry

On a rainy October night outside his home in Libreville, Gabon, Christophe Bibang explained how many Gabonese, especially those who practice Bwiti, are experiencing a shift in their relationship with iboga. The slender yellow fruit is not an unfamiliar sight, even in the tropical city, where transplanting iboga starts into personal gardens is common practice; everyone has a different reason for making sure the iconically Gabonese plant is close to home, whether for its beauty or to reap the benefits of the root. Recently, more people are buying iboga root – either lengths of bark or in powdered form – in big cities for use in urban Bwiti temples.

“A real connoisseur would go to a village to get iboga, but you can buy iboga bark in markets in cities including Libreville,” Bibang, a 57-year-old gardener, said. If the bark snaps, it’s probably iboga. If it bends, it’s a potentially lethal fake. But when it’s purchased in powder form, it’s more difficult to tell.

A nun and girls carrying candles praying around the fire with their faces painted white during a Bwiti initiation ceremony. — A nun and girls carrying candles pray with their faces painted white during a Bwiti initiation ceremony. Photograph: Jorge Fernandez/Alamy

Most iboga sold in the global market has been illegally exported from Gabon, according to Lee White, Gabon’s minister of water, forests, the sea, and environment. Authorities suspect it’s mostly poached by people coming in from neighboring countries and carried on fishing boats that get lost in the heavy sea traffic between Gabon, Cameroon and Nigeria. A gram of raw iboga root sells for about $2,000 a kilogram. Medical-grade pure ibogaine, which is extracted from the root bark, costs as much as $150,000 a kilogram. It’s often sold on online marketplaces and through social media.

“Because it’s a sacred plant in Gabon, you shouldn’t even talk about selling it. For others it’s a drug, and then again, you shouldn’t be selling it because it’s a drug. But for others, it’s a commodity that’s a business opportunity,” said White, adding that the powdered iboga root is sometimes cut with bark from a plant called Rauvolfia vomitoria. In high doses, it’s toxic, and people who have purchased tainted iboga for use in Bwiti have died.

Deaths from tainted iboga have increased as global demand for ibogaine therapy put pressure on Gabon’s natural reserves. It’s also increased incentive for vendors to sell tainted or fake iboga in markets and abroad, according to Yann Guignon, founder of Blessings of the Forest. His non-profit helps communities throughout the interior of Gabon start iboga plantations and replant what has been poached from the wild. The hope is that the 12 communities cultivating high-value iboga will serve as a pilot program that would let the country explore how it can get involved in a regulated iboga industry, putting less pressure on wild plants.

“Everyone should have access to this medicine, but in a legal, sustainable and fair way. There is no problem with companies making money, but when they potentially generate huge profits while iboga is plundered from the public domain, that is a big problem,” he said.

Gabon was the first country to sign the Nagoya Protocol on genetic resources, largely to protect its Tabernanthe iboga. The agreement creates a framework in which companies that benefit from the genetic resources of another can ensure some of the profit goes to the communities from which that resource came from. But White worries that as research on ibogaine moves forward in different directions, Gabon will not be compensated for its contribution.

“The ultimate economic negative would be if someone does invent a drug that helps cure one of these horrible diseases and they make money and Gabon makes nothing,” White said. “We wouldn’t know about this plant had it not been for the Gabonese people.”

Gabonese officials plan to meet early this year to discuss how the country’s relationship with iboga – currently a protected plant – may change in the future. Bibang and others in his community are preparing to be part of a legal and sustainable global industry if laws that prohibit the plant’s export from Gabon are lifted.

On his plot of land outside the city, Bibang is cultivating 20 iboga plants. For now, he sells the plants to people who want to plant their own backyard iboga shrubs. But he also recognizes the global interest in iboga and what doors that could open for plant experts like him.

“It’s green gold. I want to make sure I know how to grow it,” he said.